Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

被引：0
|
作者：
E Elez
A Hendlisz
T Delaunoit
J Sastre
A Cervantes
R Varea
G Chao
J Wallin
J Tabernero
机构：
[1] Vall d’Hebron Institute of Oncology Barcelona,
[2] Spain and Universitat Autònoma de Barcelona,undefined
[3] Institut Jules Bordet,undefined
[4] Centres Hospitaliers Jolimont,undefined
[5] Hospital Universitario San Carlos,undefined
[6] Biomedical Research Institute INCLIVA,undefined
[7] University of Valencia,undefined
[8] Eli Lilly and Company,undefined
[9] Eli Lilly and Company,undefined
[10] Eli Lilly and Company,undefined
来源：
British Journal of Cancer | 2016年 / 114卷
关键词：
advanced colorectal cancer; modified FOLFOX6; necitumumab; KRAS; EGFR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：372 / 380
页数：8
相关论文
共 50 条
  • [1] Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
    Elez, E.
    Hendlisz, A.
    Delaunoit, T.
    Sastre, J.
    Cervantes, A.
    Varea, R.
    Chao, G.
    Wallin, J.
    Tabernero, J.
    BRITISH JOURNAL OF CANCER, 2016, 114 (04) : 372 - 380
  • [2] Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial
    Argiles, Guillem
    Saunders, Mark P.
    Rivera, Fernando
    Sobrero, Alberto
    Benson, Al, III
    Guillen Ponce, Carmen
    Cascinu, Stefano
    Van Cutsem, Eric
    Macpherson, Iain R.
    Strumberg, Dirk
    Koehne, Claus-Henning
    Zalcberg, John
    Wagner, Andrea
    Garosi, Vittorio Luigi
    Grunert, Julia
    Tabernero, Josep
    Ciardiello, Fortunato
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (08) : 942 - 949
  • [3] A Phase II Trial of FOLFOX6 and Cetuximab in the First-line Treatment of Patients With Metastatic Colorectal Cancer
    Boccia, Ralph V.
    Cosgriff, Thomas M.
    Headley, David L.
    Badarinath, Suprith
    Dakhil, Shaker R.
    CLINICAL COLORECTAL CANCER, 2010, 9 (02) : 102 - 107
  • [4] A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer
    Okita, Natsuko T.
    Esaki, Taito
    Baba, Eishi
    Sakai, Daisuke
    Tokunaga, Shinya
    Takiuchi, Hiroya
    Mizunuma, Nobuyuki
    Nagashima, Kengo
    Kato, Ken
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (05) : 2026 - 2031
  • [5] A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer
    Natsuko T. Okita
    Taito Esaki
    Eishi Baba
    Daisuke Sakai
    Shinya Tokunaga
    Hiroya Takiuchi
    Nobuyuki Mizunuma
    Kengo Nagashima
    Ken Kato
    Investigational New Drugs, 2012, 30 : 2026 - 2031
  • [6] TRAIL Receptor Agonist Conatumumab With Modified FOLFOX6 Plus Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer
    Fuchs, Charles S.
    Fakih, Marwan
    Schwartzberg, Lee
    Cohn, Allen L.
    Yee, Lorrin
    Dreisbach, Luke
    Kozloff, Mark F.
    Hei, Yong-jiang
    Galimi, Francesco
    Pan, Yang
    Haddad, Vincent
    Hsu, Cheng-Pang
    Sabin, Antony
    Saltz, Leonard
    CANCER, 2013, 119 (24) : 4290 - 4298
  • [7] Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer
    Matsumoto, Shigemi
    Nishimura, Takafumi
    Kanai, Masashi
    Mori, Yukiko
    Nagayama, Satoshi
    Kawamura, Jun'ichiro
    Nomura, Akinari
    Miyamoto, Shin'ichi
    Kitano, Toshiyuki
    Ishiguro, Hiroshi
    Yanagihara, Kazuhiro
    Teramukai, Satoshi
    Sakai, Yoshiharu
    Chiba, Tsutomu
    Fukushima, Masanori
    CHEMOTHERAPY, 2008, 54 (05) : 395 - 403
  • [8] Phase I study of first-line sunitinib (SU) plus modified FOLFOX6 (mFOLFOX6) in Japanese patients (pts) with metastatic colorectal cancer (mCRC)
    Hamaguchi, T.
    Yoshino, T.
    Ohtsu, A.
    Yamazaki, K.
    Shimada, Y.
    Kato, K.
    Yasui, H.
    Boku, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 340 - 340
  • [9] FOLFOX6 as first-line treatment in metastatic gastric cancer: Preliminary results of a phase II trial
    Fontana, A.
    Losi, L.
    Bertolini, F.
    Zironi, S.
    Depenni, R.
    Malavasi, N.
    Scarabelli, L.
    Luppi, G.
    Conte, P. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Clinical and Economic Evaluation of First-line Therapy with FOLFIRI or Modified FOLFOX6 for Metastatic Colorectal Cancer
    Ajima, Hidetomo
    Ogata, Hiroyasu
    Fujita, Ken-ichi
    Miwa, Keisuke
    Sunakawa, Yu
    Mizuno, Keiko
    Ishida, Hiroo
    Yamashita, Keishi
    Nakayama, Hirofumi
    Kawara, Kaori
    Takahashi, Harumi
    Sasaki, Yasutsuna
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (07) : 634 - 638
12345